Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
出版年份 2015 全文链接
标题
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
作者
关键词
Renal impairment, Sitagliptin, Type 2 diabetes, Vildagliptin
出版物
DIABETOLOGIA
Volume 58, Issue 9, Pages 2020-2026
出版商
Springer Nature
发表日期
2015-06-12
DOI
10.1007/s00125-015-3655-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
- (2014) Gillian M. Keating DRUGS
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment
- (2011) E. Ritz DIABETES CARE
- Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
- (2011) M. Nowicki et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2011) Midori Ito et al. ENDOCRINE JOURNAL
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States
- (2011) Ian H. de Boer JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
- (2010) JosephA Davis et al. INDIAN JOURNAL OF PHARMACOLOGY
- Diabète et maladie rénale chronique : ce que nous apprend l’épidémiologie
- (2010) Emmanuel Villar et al. Nephrologie & Therapeutique
- Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
- (2009) Raffaele Marfella et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
- (2008) J. C. N. Chan et al. DIABETES OBESITY & METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now